Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Target ID: TTDS00016

Target Information
NameDopamine reuptake    
Type of targetSuccessful target    
SynonymsDopamine re-uptake    
DiseaseDepression
[ICD9: 311   ICD10: F32]
[1]
Obesity
[ICD9: 278   ICD10: E66]
[2]
Drug(s)CocaineApprovedAnesthetic[3]
PhenmetrazineApprovedObesity[4]
Bupropion+naltrexonePhase IIIObesity[5]
DOV 21947Phase IISevere Mood Disorders[6]
DOV-21947Phase IISevere Mood Disorders[6]
AmineptineWithdrawalSevere depressive episodes[7]
BrasofensineDiscontinuedParkinson's Disease[8]
DOV-216303Discontinued in Phase IISevere Mood Disorders[6]
GSK372475Discontinued in Phase IIADHD; Severe Mood Disorders[6]
NS 2359Discontinued in 2009 in phase II Attention-deficit/hyperactivity disorder, depression and cocaine addiction[9]
RadafaxineDiscontinued in Phase IIMajor Depressive Disorder (MDD), Bipolar disorder[10][11]
Radaxafine HClDiscontinued in 2006 due to "poor test results" in Phase INeuropathic pain[12]
Related US Patent6,410,736
6,596,741
6,677,378
6,716,868
Target ValidationClick to Find Target Validation Information.    
InhibitorAmineptine[7]
Brasofensine[8]
Bupropion+naltrexone[5]
Cocaine[3]
DOV 21947[6]
DOV-216303[6]
DOV-21947[6]
GSK372475[6]
Hypericum (St John's Wort)[1]
Indatraline[13]
NS 2359[9]
Phenmetrazine[4]
Radafaxine[10][11]
Radaxafine HCl[12]
MultitargetBupropion+naltrexone[5]
Cocaine[3]
DOV 21947[6]
DOV-216303[6]
DOV-21947[6]
GSK372475[6]
NS 2359[9]
Phenmetrazine[4]
Radafaxine[10][11]
Radaxafine HCl[12]
Cross References 3D Structure
Related Literature
On-Line Medical Dictionary
Ref 1The experimental and clinical pharmacology of St John's Wort (Hypericum perforatum L.). Mol Psychiatry. 1999 Jul;4(4):333-8. To Reference
Ref 2Regulation of dopamine transporter activity by carboxypeptidase E. Mol Brain. 2009 May 6;2(1):10. To Reference
Ref 3Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81. Epub 2009 Apr 17. To Reference
Ref 4Eur J Pharmacol. 2002 Jun 28;447(1):51-7.Interaction of the anorectic medication, phendimetrazine, and its metabolites with monoamine transporters in rat brain. To Reference
Ref 5Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50. To Reference
Ref 6Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92. Epub 2008 Jan 2. To Reference
Ref 7Amineptine in the treatment of amphetamine withdrawal: a placebo-controlled, randomised, double-blind study. J Med Assoc Thai. 1997 Sep;80(9):587-92. To Reference
Ref 8Dopamine transporter ligands: recent developments and therapeutic potential. Curr Top Med Chem. 2006;6(17):1825-43. To Reference
Ref 9Emerging drugs for attention-deficit/hyperactivity disorder. Expert Opin Emerg Drugs. 2007 Sep;12(3):423-34. To Reference
Ref 10Emerging drugs for bipolar disorder. Expert Opin Emerg Drugs. 2006 Nov;11(4):621-34. To Reference
Ref 11Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. To Reference
Ref 12Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26. To Reference
Ref 13Effects of indatraline and buprenorphine on self-administration of speedball combinations of cocaine and heroin by rhesus monkeys. Neuropsychopharmacology. 2001 Jul;25(1):104-17. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543